Phase I study of adozelesin (U-73,975) in patients with solid tumors

G. J. Shamdas, D. S. Alberts, M. Modiano, C. Wiggins, J. Power, D. A. Kasunic, G. L. Elfring, R. H. Earhart

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


During a phase I clinical and pharmacologic trial, 26 patients with refractory solid tumors were treated with increasing doses of adozelesin by brief intravenous infusion every 3 weeks. Overall, adozelesin was well tolerated. The dose-limiting toxicity was myelosuppression, mainly thrombocytopenia and leukopenia. Nonhematologic toxicity was generally mild, with fatigue (36%), local reaction at the infusion site (24%), nausea or vomiting (20%) and hypersensitivity reaction (16%) being the most common adverse effects. There were no objective clinical responses. The maximally tolerated dose on this schedule was 188 μg/m2 with the recommended phase II starting dose being 150 μg/m2 on an every 3 week schedule. Adozelesin merits broad investigation at the phase II level.

Original languageEnglish (US)
Pages (from-to)10-14
Number of pages5
JournalAnti-cancer drugs
Issue number1
StatePublished - 1994


  • U 73,975
  • adozelesin
  • chemotherapy
  • phase I

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Phase I study of adozelesin (U-73,975) in patients with solid tumors'. Together they form a unique fingerprint.

Cite this